The global ketamine treatment market is anticipated to grow at a CAGR of 43.7% during the forecast period (2023-2030). Ketamine has been widely used in the treatment of various conditions, including major depressive disorder, treatment-resistant depression (TRD), bipolar depression, post-traumatic stress disorder, anxiety disorders, chronic pain management, and migraine or headache management. Ketamine is also been used in the form of infusion therapy and nasal spray, and has been found to be effective in reducing symptoms of these conditions.
Browse the full report description of “Ketamine treatment Market Size, Share & Trends Analysis Report by Route of Administration (Oral, Infusions, and Nasal Spray), by Application (Treatment-Resistant Depression (TRD), Anxiety Disorder, Post-Traumatic Stress Disorder (PTSD), and Others), and by End User (Hospitals and Medical Centers, Specialized Ketamine Clinics, Psychiatric Hospitals, and Others), Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/ketamine-treatment-market
The primary factor supporting the market growth includes the growing demand and advancements in telehealth. Post-COVID-19 pandemic, the number of people receiving ketamine via telemedicine has been soared owing to the lockdown restrictions imposed globally by the federal government of all the nations. One rule change allowed providers to prescribe controlled substances including ketamine without first seeing the patient in person.
The adoption of telemedicine and virtual care solutions is a significant driving factor in the globally ketamine treatment market. It increases access to treatment, especially in areas where in-person options are minimal. For instance, in September 2022, Braxia Scientific Corp. launched KetaMD in Florida. KetaMD accepted new patients and finished their first ketamine treatments. Eligible patients, as determined by one of KetaMD's certified Florida healthcare practitioners, received medically supervised therapies while at home, virtually directed by registered nurses with mental health competence.
Furthermore, Ketamine has been studied for its potential in treating depression and other mood disorders which have not responded to other forms of treatment. It has been seen to offer a possible solution to those struggling with treatment-resistant conditions. in October 2023,Victoria’s first public ketamine clinic has opened It is employing the anesthetic, that is often used as a recreational substance, to assist patients suffering from difficult-to-treat depression.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Route of Administration
o By Application
o By End User
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes Core One Labs Inc., Enso Discoveries, LLC., Johnson & Johnson Pvt. Ltd., Ketamine Research Institute, Ketamine Wellness Centers, and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Ketamine Treatment Market Report Segment
By Route of Administration
By Application
By End-User
Global Ketamine Treatment Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/ketamine-treatment-market